Desocort Cream

Desocort Cream is used for: Corticosteroid-responsive dermatoses

Topical/Cutaneous Corticosteroid-responsive dermatoses Adult: As 0.05-0.25% cream/gel/lotion/oint: Apply a thin film onto affected area bid. Rub in gently.

Topical/Cutaneous Corticosteroid-responsive dermatoses Child: As 0.05-0.25% cream/gel/lotion/oint: Apply a thin film onto affected area bid. Rub in gently.

Hypersensitivity

Use caution in children; use smallest amount for shortest period of time Children may exhibit greater susceptibility to corticosteroid-induced HPA axis suppression and Cushing's syndrome due to larger skin surface area to body weight ratio Chronic topical corticosteroid therapy may interfere with growth and development in children Use med to very high potency for <2 wk to reduce local and systemic side effects Use low potency for chronic therapy Kaposi's sarcoma reported with prolonged corticosteroid therapy Avoid medium to very high potency on face, folds, groin because can increase steroid absorption Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HA) axis suppression with potential for clinical glucocorticosteroid insufficiency; this may occur during treatment or upon withdrawal of topical corticosteroid Because of potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression Factors that predispose a patient using a topical corticosteroid to HPA axis suppression include use of more potent steroids, use over large surface areas, use over prolonged periods, use under occlusion, use on an altered skin barrier, and use in patients with liver failure An ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression; if HPA axis suppression is documented, an attempt should be made to gradually withdraw drug to reduce frequency of application, or substitute a less potent steroid Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids; recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids; Cushing’s syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids Use of more than one corticosteroid-containing product at same time may increase total systemic corticosteroid exposure Local adverse reactions may be more likely to occur with occlusive use, prolonged use or use of higher potency corticosteroids; reactions may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria; some local adverse reactions may be irreversible Allergic contact dermatitis to any component of topical corticosteroids is usually diagnosed by failure to heal rather than a clinical exacerbation Clinical diagnosis of allergic contact dermatitis can be confirmed by patch testing Concomitant skin infections should be treated with appropriate antimicrobial agent; if infection persists, therapy should be discontinued until infection has been adequately treated Monitoring Parameters Monitor for hypothalamic-pituitary-adrenal (HPA) axis suppression through ACTH stimulation or urinary free cortisol test.

Pregnancy There are no available data on use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes; observational studies suggest maternal use of high to super-high potency topical steroids; may be associated with an increased risk of low birthweight infants; advise pregnant woman that therapy may increase potential risk of low birth weight infants and to use drug on the smallest area of skin and for shortest duration possible Desoximetasone has been shown to cause malformations and be embryotoxic in mice, rats, and rabbits when given by subcutaneous or dermal routes of administration at doses 3 to 30 times the human dose based on a body surface area comparison Lactation There is no information on presence of topically administered desoximetasone in human milk, effects on breastfed infant, or on milk production; not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk; the developmental and health benefits of breastfeeding should be considered along with mother's clinical need for therapy and any potential adverse effects on breastfed infant from therapy or from underlying maternal condition To minimize potential exposure to breastfed infant via breast milk, use spray on smallest area of skin and for shortest duration possible while breastfeeding; advise breastfeeding women not to apply spray directly to nipple and areola to avoid direct infant exposure

May diminish the antineoplastic effect of aldesleukin. May potentiate the hyperglycaemic effect of ceritinib. May diminish the therapeutic effect of corticorelin and hyaluronidase. May enhance the adverse/toxic effects of deferasirox.

Side effects of Desoximetasone Topical : Frequency Not Defined Skin atrophy Striae Acneform lesions Pruritus Irritation Miliaria Folliculitis Erythema Hypopigmentation Vesiculation Pigmentation changes HPA suppression (with higher potency used >2 wk)

Desoximetasone is a topical corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins) and sequentially inhibits the release of arachidonic acid hence depresses the formation, release, and activity of endogenous chemical mediators such as kinins, histamine, liposomal enzymes, and prostaglandins.

Desocort 0.25% Cream manufactured by Incepta Pharmaceuticals Ltd.. Its generic name is Desoximetasone Topical. Desocort is availble in Bangladesh. Farmaco BD drug index information on Desocort Cream is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.